Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand

Author:

Carroll Alistair12ORCID,Bayes Adam12ORCID,Montebello Mark345,Brett Jonathan6789,Arunogiri Shalini1011ORCID,Saunders John B12,Loo Colleen K1213ORCID

Affiliation:

1. Neuromodulation and Interventional Psychiatry, Black Dog Institute, Sydney, NSW, Australia

2. Psychiatry & Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia

3. Drug and Alcohol Services, Northern Sydney Local Health District, St Leonards, NSW, Australia

4. Specialty of Addiction Medicine, The University of Sydney, Camperdown, NSW, Australia

5. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia

6. Clinical Pharmacology & Toxicology and Addiction Medicine, St Vincent’s Hospital, Sydney, NSW, Australia

7. NSW Poisons Information Centre, The Children’s Hospital at Westmead, NSW, Australia

8. St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia

9. Medicines and Health Intelligence, School of Population Health, University of New South Wales, Sydney, NSW, Australia

10. Statewide Addiction and Mental Health Centre, Turning Point, Eastern Health, Melbourne, VIC, Australia

11. Monash Addiction Research Centre, Monash University, Melbourne, VIC, Australia

12. National Centre for Youth Substance Use Research, The University of Queensland, Brisbane, QLD, Australia

13. Cardiovascular program. The George Institute for Global Health, Sydney, NSW, Australia

Abstract

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict use in those with drug dependence. There is substantial variation in definitions of drug dependence used in each jurisdiction, and between the legal and clinical definitions, with the latter specified in the current International Classification of Diseases, Eleventh Revision and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. This paper reviews the literature assessing the risk of ketamine misuse and dependence in patients with a history of illicit drug use, abuse or dependence and presents recommendations for psychiatrists who prescribe ketamine in such patients with treatment-resistant depression.

Publisher

SAGE Publications

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3